Pfizer (PFE)
24.29
+0.32 (1.34%)
NYSE · Last Trade: Jun 10th, 2:57 PM EDT
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Via Investor's Business Daily · June 10, 2025
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Via The Motley Fool · June 10, 2025
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."
Via Stocktwits · June 10, 2025

Via Benzinga · May 29, 2025
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Via Investor's Business Daily · June 9, 2025
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.
Via Stocktwits · June 9, 2025
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Via Chartmill · June 9, 2025
The meeting follows an executive order from President Trump last month, which directed drugmakers to lower medicine prices to the levels paid by other high-income countries.
Via Stocktwits · June 9, 2025
Via Benzinga · June 9, 2025
Via The Motley Fool · June 8, 2025

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients
Via Benzinga · June 6, 2025

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.
Via Benzinga · June 6, 2025

Via The Motley Fool · June 5, 2025

A volatile stock market represents an ideal opportunity for long-term investors to pounce.
Via The Motley Fool · June 5, 2025

Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet.
Via Benzinga · June 3, 2025

Apple and Cisco could generate surprising gains over the next few years.
Via The Motley Fool · June 3, 2025

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.
Via The Motley Fool · June 3, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.
Via StockStory · June 1, 2025

The business may be somewhat boring, but it consistently delivers year after year, resulting in tremendous long-term returns.
Via The Motley Fool · June 1, 2025

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 trial.
Via Benzinga · May 30, 2025

Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Via StockStory · May 30, 2025